Canaccord Genuity Maintains Buy on Corcept Therapeutics, Lowers Price Target to $32
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $33 to $32.
Corcept Therapeutics To Pay $14M On Proposed Settlement Of Purported Securities Class Action
Corcept has reached a preliminary settlement of all claims in the purported securities class action against Corcept and certain of its executive officers captioned Melucci v. Corcept Therapeutics Incorporated,
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Corcept Therapeutics’s Earnings: A Preview
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement.
Analysts estimate that Corcept Therapeutics will report an earnings per share (EPS) of $0.22.
Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study
Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial In Recurrent, Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Preview: Corcept Therapeutics’s Earnings
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Corcept Therapeutics will report an earnings per share (EPS) of $0.24.
Corcept Therapeutics Completes Enrollment In Phase 2 GRATITUDE Study Of Miricorilant In Patients With Antipsychotic-Induced Weight Gain
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the